Literature DB >> 35073177

Letter by Costantine et al Regarding Article, "Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia".

Maged M Costantine1, Kirsten Lawrence-Cleary2, Georges Saade3, Ronald J Wapner4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35073177      PMCID： PMC8820507          DOI： 10.1161/CIRCULATIONAHA.121.056728

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  4 in total

1.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Authors:  Keiichi Kumasawa; Masahito Ikawa; Hiroyasu Kidoya; Hidetoshi Hasuwa; Tomoko Saito-Fujita; Yuka Morioka; Nobuyuki Takakura; Tadashi Kimura; Masaru Okabe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice.

Authors:  Nicola Garrett; Joaquim Pombo; Michelle Umpierrez; James E Clark; Mark Simmons; Guillermina Girardi
Journal:  JCI Insight       Date:  2018-04-19

3.  A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.

Authors:  Maged M Costantine; Holly West; Katherine L Wisner; Steve Caritis; Shannon Clark; Raman Venkataramanan; Catherine S Stika; Erik Rytting; Xiaoming Wang; Mahmoud S Ahmed
Journal:  Am J Obstet Gynecol       Date:  2021-05-24       Impact factor: 8.661

4.  Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.

Authors:  Moritz Döbert; Anna Nektaria Varouxaki; An Chi Mu; Argyro Syngelaki; Anca Ciobanu; Ranjit Akolekar; Catalina De Paco Matallana; Simona Cicero; Elena Greco; Mandeep Singh; Deepa Janga; Maria Del Mar Gil; Jacques C Jani; José Luis Bartha; Kate Maclagan; David Wright; Kypros H Nicolaides
Journal:  Circulation       Date:  2021-06-24       Impact factor: 29.690
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.